QQ客服 官方微博 反馈留言

	Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
	Ma Fei; Ouyang Quchang; Li Wei; Jiang Zefei; Tong Zhongsheng; Liu Yunjiang; Li Huiping; Yu Shiying; Feng Jifeng; Wang Shusen
	2019
卷号	37期号:29页码:2610-2619
ISSN号	1527-7755
DOI	10.1200/JCO.19.00108
URL标识	查看原文
收录类别	PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6338265
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Ma Fei,Ouyang Quchang,Li Wei,et al. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study[J],2019,37(29):2610-2619.
APA	Ma Fei.,Ouyang Quchang.,Li Wei.,Jiang Zefei.,Tong Zhongsheng.,...&Xu Binghe.(2019).Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.,37(29),2610-2619.
MLA	Ma Fei,et al."Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study".37.29(2019):2610-2619.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。